A feasibility study of an unsupervised, pre-operative exercise program for adults with lung cancer

Eur J Cancer Care (Engl). 2020 Jul;29(4):e13254. doi: 10.1111/ecc.13254. Epub 2020 May 29.

Abstract

Objective: The purpose of this study was to explore the feasibility, acceptability and perceived utility of the provision of a wearable fitness device and an exercise prescription from a surgeon, prior to surgery for lung cancer.

Methods: A single-arm, pre-post feasibility study was conducted with 30 participants scheduled for surgery to treat stage I, II or III lung cancer. Participants were given a Garmin Vivoactive HR device and a prescription for 150 min of moderately to vigorous exercise per week. Participants completed assessments on four occasions and completed a semi-structured interview on two occasions. Descriptive statistics were used to assess the feasibility and acceptability of study procedures, including synchronising the Garmin device and engaging in study assessments.

Results: Seventy-nine per cent of enrolled participants completed the pre-operative study activities. Seventy-one per cent of enrolled participants successfully synchronised their device during the pre-operative period. Data were transmitted from the device to the study team for an average of 70% of the pre-operative days.

Conclusion: This pilot study demonstrated the feasibility and acceptability of a pre-operative exercise program for patients scheduled to undergo surgery for lung cancer.

Trial registration: The study protocol was registered with ClinicalTrials.gov prior to the initiation of participant recruitment (NCT03162718).

Keywords: exercise; fitness tracker; neoplasms; rehabilitation; telemedicine; thoracic surgery.

MeSH terms

  • Aged
  • Exercise Therapy / methods*
  • Feasibility Studies
  • Female
  • Fitness Trackers*
  • Humans
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Patient Acceptance of Health Care*
  • Pilot Projects
  • Preoperative Exercise*

Associated data

  • ClinicalTrials.gov/NCT03162718